GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Financial Strength

Biomerica (Biomerica) Financial Strength : 6 (As of Feb. 2024)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica Financial Strength?

Biomerica has the Financial Strength Rank of 6.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Biomerica's interest coverage with the available data. Biomerica's debt to revenue ratio for the quarter that ended in Feb. 2024 was 0.21. As of today, Biomerica's Altman Z-Score is -4.68.


Competitive Comparison of Biomerica's Financial Strength

For the Medical Devices subindustry, Biomerica's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Financial Strength distribution charts can be found below:

* The bar in red indicates where Biomerica's Financial Strength falls into.



Biomerica Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Biomerica's Interest Expense for the months ended in Feb. 2024 was $0.00 Mil. Its Operating Income for the months ended in Feb. 2024 was $-2.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $0.54 Mil.

Biomerica's Interest Coverage for the quarter that ended in Feb. 2024 is

GuruFocus does not calculate Biomerica's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Biomerica Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Biomerica's Debt to Revenue Ratio for the quarter that ended in Feb. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Feb. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.319 + 0.543) / 4.068
=0.21

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Biomerica has a Z-score of -4.68, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -4.68 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomerica  (NAS:BMRA) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Biomerica has the Financial Strength Rank of 6.


Biomerica Financial Strength Related Terms

Thank you for viewing the detailed overview of Biomerica's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663